CN115252739A

CN115252739A - Traditional Chinese medicine composition for treating cardiovascular diseases and application thereof

Info

Publication number: CN115252739A
Application number: CN202210810552.3A
Authority: CN
Inventors: 杨雪松; 杨洁; 陈永志; 杨传华
Original assignee: Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Current assignee: Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Priority date: 2022-07-11
Filing date: 2022-07-11
Publication date: 2022-11-01
Anticipated expiration: 2042-07-11
Also published as: CN115252739B

Abstract

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating cardiovascular diseases and application thereof. The traditional Chinese medicine composition mainly comprises radix bupleuri, fructus aurantii, radix curcumae, rhizoma cyperi, ligusticum wallichii, lumbricus, leech, radix paeoniae rubra and peach kernel, has the effects of regulating qi, promoting qi and activating blood circulation, can obviously relieve symptoms such as chest distress, chest pain, palpitation and short breath caused by coronary heart disease, and can improve the blood fat level and achieve 96.67% of clinical treatment effective rate of hemorheology. Animal experiments show that the traditional Chinese medicine composition has a good treatment effect on experimental rat coronary heart disease, can obviously reduce the expression of a rat myocardial injury marker, improve the immunohistochemical expression of cardiac muscle neovascularization VEGF protein, and improve the function of vascular endothelium.

Description

Traditional Chinese medicine composition for treating cardiovascular diseases and application thereof

Technical Field

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating cardiovascular diseases and application thereof.

Background

Coronary heart disease, which is called coronary atherosclerotic heart disease and sometimes called ischemic heart disease, refers to heart disease caused by myocardial ischemia and anoxia caused by coronary atherosclerosis.

According to statistics, the number of people dying from angina pectoris due to coronary heart disease is more than ten million every year all over the world, and the death seriously harms the health and the life of human beings, particularly middle-aged and old people. At present, western medicines for treating coronary heart disease mainly comprise nitrate compounds, B receptor blockers, calcium antagonists and the like, and the medicines can only relieve symptoms, are difficult to treat the root cause, and have certain toxic and side effects; the coronary heart disease is called as 'obstruction of qi in the chest' in traditional Chinese medicine, and the coronary heart disease is clinically mainly manifested as chest stuffiness and pain, palpitation, short breath, even chest pain and bone fracture, and is a common disease and frequently encountered diseases, and patients are mostly aged and elderly people, and if the treatment is not timely, the patients can suffer from secondary myocardial infarction and even die. The traditional Chinese medicine considers that the etiology and pathology of coronary heart disease and angina pectoris are ' heart-blood fatigue stagnation, heart-vessel obstruction and obstruction leading to pain ' caused by imbalance of yin and yang and disorder of qi activity '.

At present, most of Chinese patent medicines used for treating coronary heart disease and angina pectoris in the clinical practice of traditional Chinese medicine, such as compound salvia tablets, salvia tablets and the like, have the defects of incomplete medication, low curative effect and slow response, and are often required to be combined with a plurality of medicines for medication. Although the action intensity of a single target point of the traditional Chinese medicine is lower than that of western medicine, the characteristics of multiple ways, multiple target points, dynamic overall treatment and small toxic and side effects of the traditional Chinese medicine are far beyond the reach of the western medicine, and the comprehensive treatment effect of the Chinese patent medicine with definite curative effect is better than that of the western medicine. But the conventional traditional Chinese medicine has long treatment time, and is difficult to radically cure the coronary heart disease.

Disclosure of Invention

The invention overcomes the defects of the prior art, and provides the traditional Chinese medicine composition which has obvious effect on treating coronary heart disease and relieving symptoms caused by coronary heart disease.

Specifically, the technical scheme of the invention is as follows:

the first purpose of the invention is to provide a traditional Chinese medicine composition which comprises, by weight, 5-80 parts of radix bupleuri, 20-100 parts of fructus aurantii, 6-90 parts of radix curcumae, 40-100 parts of rhizoma cyperi, 20-100 parts of ligusticum wallichii, 5-50 parts of lumbricus, 2-40 parts of leech, 20-100 parts of radix paeoniae rubra and 5-80 parts of peach kernel.

Further, the traditional Chinese medicine composition comprises, by weight, 10-100 parts of pericarpium citri reticulatae viride, 20-100 parts of pericarpium citri reticulatae, 80-200 parts of angelica sinensis, 100-300 parts of radix rehmanniae, 5-100 parts of safflower, 20-300 parts of radix achyranthis bidentatae, 2-20 parts of asarum and 120-200 parts of platycodon grandiflorum.

Specifically, the traditional Chinese medicine composition comprises the following components:

20-60 parts of green tangerine peel, 50-80 parts of dried orange peel, 60-90 parts of rhizoma cyperi, 10-50 parts of radix curcumae, 100-150 parts of angelica sinensis, 150-220 parts of radix rehmanniae, 9-50 parts of peach kernel, 9-40 parts of safflower, 12-50 parts of radix bupleuri, 30-60 parts of red paeony root, 40-90 parts of radix achyranthis bidentatae, 3-10 parts of asarum, 12-30 parts of earthworm, 6-20 parts of leech, 40-80 parts of ligusticum wallichii, 130-150 parts of platycodon grandiflorum and 40-60 parts of fructus aurantii.

The second purpose of the invention is to provide the medical application of the traditional Chinese medicine composition, in particular to the application in the medicine for treating cardiovascular diseases.

Further, the cardiovascular disease is coronary heart disease.

Further, the coronary heart disease comprises myocardial infarction, myocardial ischemia, angina pectoris.

Furthermore, the traditional Chinese medicine composition can relieve and/or improve symptoms of hypodynamia, chest distress and chest pain caused by coronary heart disease.

Furthermore, the traditional Chinese medicine composition can reduce lipid and improve blood rheology.

Furthermore, the traditional Chinese medicine composition can be prepared into a preparation directly or after pharmaceutically acceptable auxiliary materials are added.

The third purpose of the invention is to provide a pharmaceutical composition, which comprises the traditional Chinese medicine composition, and the pharmaceutical composition also comprises a chemical medicine capable of treating coronary heart disease.

The Chinese medicinal composition can be used in combination with chemical medicines for treating coronary heart disease, and has improved curative effect.

Compared with the prior art, the invention has the beneficial effects that:

(1) Clinical case statistics shows that the traditional Chinese medicine composition can obviously relieve symptoms of chest distress, chest pain, palpitation, short breath and the like caused by coronary heart disease, improve indexes of blood fat level, blood rheology and the like, and the clinical treatment effective rate reaches 96.67%.

(2) Pharmacodynamic experiments show that the traditional Chinese medicine composition has a good treatment effect on experimental rat coronary heart disease, can obviously reduce the expression of a rat myocardial injury marker, improve the immunohistochemical expression of cardiac muscle neovascularization VEGF protein, and improve the function of vascular endothelium.

Drawings

FIGS. 1 to 3: content levels of CK-MB, c-TNT and LDH in rat aorta blood serum

FIGS. 4-5: immunohistochemical expression of angiogenesis VEGF protein in myocardial of infarct marginal zone of each group of rats-descriptive statistical data, multiple comparison of significance difference

FIGS. 6-7: TXB in rat plasma₂、6-Keto-PGF_1αExpression of content

FIGS. 8 to 9: NO expression level-descriptive statistics, significance difference multiple comparisons in rat serum

FIG. 10: rat serum plasma ET-1 expression levels

Detailed Description

In order to make the purpose and technical solution of the present invention more clear, the present invention is further described with reference to the following examples, but the scope of the present invention is not limited to these examples, and the examples are only used for explaining the present invention. It will be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true scope of the invention.

Example 1 decoction

The formula is as follows:

5g of radix bupleuri, 15g of fructus aurantii, 5g of radix curcumae, 20g of rhizoma cyperi, 10g of ligusticum wallichii, 5g of lumbricus, 2g of leech, 10g of radix paeoniae rubra and 5g of peach kernel.

The preparation method comprises the following steps:

the preparation is prepared according to the formula, water is added to decoct to 300ml, 1 dose is taken every day, and the medicine is taken warmly 2 times in the morning and at night, 150ml each time.

Example 2 decoction

The formula is as follows:

1g of radix bupleuri, 4g of fructus aurantii, 1.2g of radix curcumae, 8g of rhizoma cyperi, 4g of ligusticum wallichii, 1g of earthworm, 0.4g of leech, 4g of radix paeoniae rubra, 1g of peach kernel, 2g of pericarpium citri reticulatae viride, 4g of pericarpium citri reticulatae, 16g of angelica sinensis, 20g of radix rehmanniae, 1g of safflower carthamus, 4g of radix achyranthis bidentatae, 0.4g of asarum and 24g of platycodon grandiflorum.

The preparation method comprises the following steps:

Example 3 decoction

The formula is as follows:

4g of radix bupleuri, 5g of fructus aurantii, 4.5g of radix curcumae, 5g of rhizoma cyperi, 5g of ligusticum wallichii, 2.5g of lumbricus, 2g of leech, 5g of radix paeoniae rubra, 4g of peach kernel, 5g of pericarpium citri reticulatae viride, 5g of pericarpium citri reticulatae, 10g of angelica sinensis, 15g of radix rehmanniae, 5g of safflower carthamus, 15g of radix achyranthis bidentatae, 1g of asarum and 10g of platycodon grandiflorum.

The preparation method comprises the following steps:

Example 4 decoction

The formula is as follows:

3g of green tangerine peel, 7.5g of tangerine peel, 9g of nutgrass galingale rhizome, 1.5g of turmeric root-tuber, 15g of Chinese angelica, 22.5g of dried rehmannia root, 1.35g of peach seed, 1.35g of safflower, 1.8g of Chinese thorowax root, 4.5g of red paeony root, 6g of twotooth achyranthes root, 0.45g of manchurian wildginger, 1.8g of earthworm, 0.9g of leech, 6g of szechuan lovage rhizome, 19.5g of platycodon root and 6g of bitter orange.

The preparation method comprises the following steps:

the preparation is prepared according to the formula, is decocted to 300ml by adding water, is taken 1 dose per day, and is taken warmly 2 times in the morning and evening, 150ml each time.

Example 5 decoction

The formula is as follows:

4.8g of green tangerine peel, 6.4g of dried orange peel, 7.2g of nutgrass galingale rhizome, 4g of turmeric root-tuber, 12g of Chinese angelica, 17.6g of dried rehmannia root, 4g of peach seed, 3.2g of safflower, 4g of Chinese thorowax root, 4.8g of red paeony root, 7.2g of twotooth achyranthes root, 0.8g of manchurian wildginger, 2.4g of earthworm, 1.6 g of leech, 6.4g of szechuan lovage rhizome, 12g of platycodon root and 4.8g of bitter orange.

The preparation method comprises the following steps:

Example 6 decoction

The formula is as follows:

4.5g of green tangerine peel, 5.5g of dried orange peel, 6.5g of nutgrass galingale rhizome, 4g of turmeric root-tuber, 12.5g of Chinese angelica, 18.5g of dried rehmannia root, 2.5g of peach seed, 2g of safflower, 3g of Chinese thorowax root, 5g of red paeony root, 6g of twotooth achyranthes root, 0.4g of manchurian wildginger, 1.8g of earthworm, 1.4g of leech, 7g of szechuan lovage rhizome, 14g of platycodon root and 5g of bitter orange.

The preparation method comprises the following steps:

Example 7 granules

50g of green tangerine peel, 80g of dried orange peel, 90g of rhizoma cyperi, 50g of radix curcumae, 140g of angelica sinensis, 215g of radix rehmanniae, 50g of peach kernel, 40g of safflower, 50g of radix bupleuri, 60g of radix paeoniae rubra, 90g of radix achyranthis bidentatae, 10g of asarum, 30g of earthworm, 20g of leech, 80g of rhizoma ligustici wallichii, 150g of platycodon grandiflorum and 60g of fructus aurantii, decocting the raw materials with water, filtering the decoction, concentrating the decoction into thick paste with the relative density of 1.15-1.25, drying the thick paste, crushing the dried thick paste into fine powder, adding a proper amount of dextrin, uniformly mixing, granulating and drying the fine powder to prepare 100g of granules. (once 5g twice a day)

EXAMPLE 8 tablets

50g of green tangerine peel, 80g of dried orange peel, 90g of rhizoma cyperi, 50g of radix curcumae, 140g of angelica sinensis, 215g of radix rehmanniae, 50g of peach kernel, 40g of safflower, 50g of radix bupleuri, 60g of radix paeoniae rubra, 90g of radix achyranthis bidentatae, 10g of asarum, 30g of earthworm, 20g of leech, 80g of rhizoma ligustici wallichii, 135g of platycodon grandiflorum and 60g of fructus aurantii, decocting the decoction in water, filtering the decoction, concentrating the decoction into thick paste with the relative density of 1.10-1.20, drying, crushing into fine powder, adding a proper amount of dextrin, uniformly mixing, granulating, drying and tabletting to obtain 100 tablets. (5 tablets at a time, twice a day)

Example 9 mixture

50g of green tangerine peel, 80g of dried orange peel, 90g of rhizoma cyperi, 50g of radix curcumae, 140g of angelica, 215g of radix rehmanniae, 50g of peach kernel, 40g of safflower, 50g of radix bupleuri, 60g of red paeony root, 90g of radix achyranthis bidentatae, 10g of asarum, 30g of earthworm, 20g of leech, 80g of rhizoma ligustici wallichii, 135g of platycodon grandiflorum and 60g of fructus aurantii, adding water for decoction, filtering and concentrating the decoction, adding a proper amount of sucrose and sodium benzoate to 200ml, stirring uniformly, and subpackaging to obtain the oral liquid. (10 ml once, twice a day)

Example 10 mixture

20g of green tangerine peel, 50g of dried orange peel, 60g of rhizoma cyperi, 10g of radix curcumae, 100g of angelica, 150g of radix rehmanniae, 9g of peach kernel, 9g of safflower, 12g of radix bupleuri, 30g of red paeony root, 40g of achyranthes root, 3g of asarum, 12g of earthworm, 6g of leech, 40g of ligusticum wallichii, 130g of platycodon grandiflorum and 40g of fructus aurantii, decocting the mixture with water, filtering and concentrating the decoction, adding a proper amount of sucrose and sodium benzoate to 200ml, stirring uniformly, and subpackaging to obtain the oral liquid. (10 ml each time, twice a day)

Example 11 mixture

60g of green tangerine peel, 80g of dried orange peel, 90g of rhizoma cyperi, 50g of radix curcumae, 150g of angelica, 220g of radix rehmanniae, 50g of peach kernel, 40g of safflower, 50g of radix bupleuri, 60g of red paeony root, 90g of radix achyranthis bidentatae, 10g of asarum, 30g of earthworm, 20g of leech, 80g of rhizoma ligustici wallichii, 150g of platycodon grandiflorum and 60g of fructus aurantii, adding water for decoction, filtering and concentrating the decoction, adding a proper amount of sucrose and sodium benzoate to 200ml, stirring uniformly, and subpackaging to obtain the oral liquid. (10 ml each time, twice a day)

Comparative example 1

12g of radix bupleuri, 12g of ligusticum wallichii, 12g of angelica sinensis, 6g of liquorice, 12g of radix rehmanniae, 12g of fructus aurantii, 12g of peach kernel, 15g of medicinal cyathula root, 6g of safflower, 6g of platycodon grandiflorum and 15g of red paeony root, decocting the decoction in water, filtering and concentrating the decoction to 40ml.

Comparative example 2

10g of radix bupleuri, 10g of dried orange peel, 10g of ligusticum wallichii, 10g of angelica sinensis, 10g of radix rehmanniae, 10g of peach kernel, 10g of safflower, 10g of fructus aurantii, 15g of red paeony root, 10g of platycodon grandiflorum, 15g of medicinal cyathula root and 5g of liquorice, decocting the decoction in water, filtering and concentrating the decoction to 40ml.

Comparative example 3

6g of dried orange peel (stir-fried with vinegar), 6g of radix bupleuri, 5g of ligusticum wallichii, 5g of rhizoma cyperi, 6g of fructus aurantii (stir-fried with bran), 5g of Chinese herbaceous peony, 3g of liquorice (roasted), 12g of peach kernel, 9g of safflower, 9g of angelica, 9g of radix rehmanniae recen, 9g of achyranthes bidentata and 5g of platycodon grandiflorum are decocted with water, and the decoction is filtered and concentrated to 40ml.

Case analysis

1. Inclusion and exclusion criteria

1.1 inclusion criteria

(1) (ii) compliance with the revised CHD angina diagnostic criteria of the World Health Organization (WHO) and International society for cardiology (ISFC);

(2) The middle energizer meets the diagnosis standard of qi deficiency and blood stasis in the internal medicine of traditional Chinese medicine.

(3) The patient is 18-80 years old;

(4) According to the principle that the patient voluntarily carries out the test, the patient voluntarily receives the drug therapy at the same time, and the doctor is matched to ensure the completeness of the treatment course.

1.2. Exclusion criteria

(1) Do not meet the inclusion criteria;

(2) Excluding pregnant and lactating women;

(3) Severe disease with severe primary heart, liver, lung, kidney, blood or affecting their survival;

(4) Allergic constitution, for example, to those known to be allergic to the present medicinal ingredients.

(5) Patients who do not actively cooperate with doctors for treatment and can not ensure the treatment course;

(6) Other clinical studies are ongoing or have been enrolled during the last 3 months.

2. Case data

2.1 general data

60 patients who were admitted to the hospital for coronary heart disease complicated with angina pectoris from 2021 year 4 to 2022 year 4 were screened and all patients were randomized into two groups:

in the 30 cases of the conventional group: 19 men with a percentage of 63.3 percent and 11 women with a percentage of 36.6 percent, the age is 40-71 years, and the average (57.21 +/-7.06) years; the time is 1-10 years, and the average (5.07 +/-2.11) year; the frequency of pain attacks is 4-10 times/month, and the average (7.66 +/-2.31) times/month; the chest pain lasts for 2-10min, and the average (6.51 + -2.78) min.

In 30 observation groups: 20 male cases accounting for 66.6 percent, 10 female cases accounting for 33.3 percent, age 41-71 years, average (56.91 +/-6.83) years; the disease onset time is 1-10 years, and the average (4.97 +/-1.89) years; the frequency of pain attacks is 4-10 times/month, with the average (7.81 ± 2.18) times/month; the chest pain lasts for 2-10min, and the average (6.64 + -2.69) min.

The comparison of the basic data of the patients in the conventional group and the observation group has no statistical significance, and P is more than 0.05, so that the research can be carried out.

3. Method of producing a composite material

3.1 methods of treatment

Conventional group: for 30 cases of patients in the conventional group, the western medicines are treated by orally taking aspirin enteric-coated tablets for 100 mg/time and 1 time/d; isosorbide mononitrate tablets are orally taken at 20 mg/time and 2 times/d; rosuvastatin is orally administered at a dose of 10 mg/time, 1 time per day, and is administered by adjusting with proper amount according to medical advice, and sublingual nitroglycerin tablet is administered for 1 month.

Observation group: the decoction of example 6 was administered to 30 patients in the observation group on the basis of the above-mentioned conventional group therapy, 1 dose per day, and 150ml of each was warm-taken in the morning and evening for 1 month continuously.

Patients in both the conventional group and the observation group fasted stimulated, greasy and cold foods during treatment and performed self-psychology adjustments to avoid mood swings and to avoid strenuous exercise.

3.2 Observation index

The treatment effects of the patients in the conventional group and the observation group are comprehensively evaluated after 30 days of treatment, and the change is observed according to indexes such as traditional Chinese medicine syndrome integral, blood fat level, hemorheology and the like.

The Chinese medicine symptom integral is evaluated according to the relevant standards of the Chinese medicine new drug clinical research guiding principle, the symptom degree of a patient is mainly divided into 0, 1, 2 and 3 points, the total point is 18 points, and the higher the point is, the more serious the symptom is.

The curative effect of the traditional Chinese medicine symptoms is divided into obvious effect, effective effect and ineffective effect according to the judgment standard of the curative effect of the traditional Chinese medicine symptoms in the clinical research guiding principle of new traditional Chinese medicines.

The effect is shown: the syndrome score after treatment is reduced by more than or equal to 70 percent;

the method has the following advantages: the syndrome score after treatment is reduced by more than or equal to 30 percent;

and (4) invalidation: the reduction in the integral of symptoms after treatment was < 30%.

3.3 statistical methods

Statistical analysis is carried out on the obtained data by adopting SPSS22.0 software, and the data is measured

Is represented by P<0.05 The difference is statistically significant.

4. Results

4.1 statistics of Chinese medicine symptom integration results

Before treatment, the difference of the traditional Chinese medicine symptom integrals of the cases in the conventional group and the observation group in the 2 groups has no obvious statistical significance (P is more than 0.05), and the traditional Chinese medicine symptom integrals after the observation group is treated are obviously lower than those in the conventional group (P is less than 0.05), so that the observation group treatment medicine can obviously improve and relieve symptoms of chest distress, chest pain, palpitation, shortness of breath and the like. See table 1.

TABLE 1 comparison of the scores of the syndromes before and after treatment for patients in the conventional group and the observation group

4.2 blood lipid level statistics

Before treatment, the difference of blood lipid levels of the cases in the conventional group and the observation group 2 has no obvious statistical significance (P is more than 0.05), and the content levels of TC (total cholesterol) and LDL-C (low density lipoprotein-cholesterol) after the observation group is treated are obviously lower than that in the conventional group (P is less than 0.05). See table 2.

TABLE 2 comparison of blood lipid levels before and after treatment in patients in the conventional and observed groups

4.3 statistics of hemorheology results

Before treatment, the hemorheology difference of the cases of the conventional group and the observation group 2 has no obvious statistical significance (P is more than 0.05), and the whole blood viscosity and the degree of the hematocrit after the treatment of the observation group are obviously lower than those of the conventional group (P is less than 0.05). See table 3.

TABLE 3 comparison of hemorheology before and after treatment between the patients in the conventional group and the observed group

Therefore, the observation of the group of medicines can obviously improve and relieve symptoms such as chest distress, chest pain, palpitation, short breath and the like, and has the obvious functions of reducing fat and improving blood rheology.

4.4 statistics of efficacy

TABLE 4 comparison of post-treatment efficacy (n/(%)) in the patients of the conventional and observation groups

Group of	Number of examples	Show effect	Is effective	Invalidation	Total effective rate
						General group	30	10/(33.33)	15/(50.00)	5/(16.67)	83.33
Observation group	30	13/(43.33)	16/(53.33)	1/(3.33)	96.67

The total effective rate of the conventional group is 83.33%, the total effective rate of the treatment group is 96.67%, and the total effective rate of the treatment group is obviously higher than that of the conventional group, which is shown in table 4.

Pharmacodynamic experiment

In order to verify the application and the mechanism of the traditional Chinese medicine composition in treating coronary heart disease, the inventor carries out related pharmacodynamic test research. It should be noted that the medicines selected in the pharmacodynamic tests below are the medicines obtained by the representative formula and the preparation method thereof; the inventor also conducts pharmacodynamic experiments on the medicines obtained by the other formulas and the preparation methods, and the experimental results show that the medicines obtained by the other formulas and the preparation methods have the same or similar effects, but the medicines are not exhaustive due to space limitations.

In addition, the pharmacodynamic experiments described below only take part of animal models as examples to verify the efficacy of the invention, and the inventor also performs related pharmacodynamic experiments on other types of coronary heart diseases mentioned in the invention, and the experimental results show that the coronary heart diseases have the same or similar effects, and are not exhaustive.

The inventor explains that the following experimental studies are carried out on the basis of the safety of the drug proved by acute toxicity tests and long-term toxicity tests, and the administration dose in the experimental studies is within a safe dose range.

The traditional Chinese medicine composition has the treatment effect on experimental rat coronary heart disease

1. Therapeutic action of traditional Chinese medicine composition on experimental myocardial infarction rats

1 Material

1.1 animals:

SD rat, SPF grade, 180-220g, laboratory animal license number: SYXK (U) 2018 0008, supplied by Luonan pharmaceutical group, inc. was acclimatized for one week prior to the experiment.

1.2 drugs

1.2.1 medicaments

Example 7 granules according to the invention

Example 9 mixture of the present invention

Example 10 mixture of the present invention

Example 11 mixture of the present invention

Qi-tonifying dripping pill containing astragalus root and ginseng

1.2.2 doses

Example 7 granules of the invention: 0.9g/kg

Example 9 of the present invention mixture: 0.9ml/kg (low dose), 1.8ml/kg (medium dose), 3.6ml/kg (high dose)

Example 10 mixture of the present invention: 1.8ml/kg

Example 11 of the present invention mixture: 1.8ml/kg

Qishen Yiqi dripping pill; 0.135g/kg

2. Modeling, grouping and administering drugs

2.1 myocardial infarction rat modeling method

The molding method comprises the following steps: taking 90 rats, anaesthetizing, connecting a respirator, inserting a tube, opening the chest to expose the heart, seeing the beginning part of the descending branch of the left coronary artery between the lower edge of the left auricle and the cone of the pulmonary artery, ligating the coronary artery at a position 0.1-0.2mm away from the lower edge of the left auricle, observing for several minutes, after thoroughly stopping bleeding, carrying out intramuscular injection of sodium penicillin 2 × 10 after layer-by-layer chest closure⁵U/d, qd, continuous 3d anti-infective.

And on the third day after operation, after sevoflurane is inhaled and anesthetized, observing the heart color Doppler ultrasound detection molding effect, measuring EF% according to the pulsation amplitude of the left ventricular myocardium, and removing the unqualified model. (removing patients with infarct size not reaching 30-40% of left ventricle, removing patients with infarct size exceeding the requirement, and removing serious hydropericardium)

2.2 grouping

Totally 84 rats are successfully molded, and 80 rats which are successfully molded are randomly divided into a model group, an example 7 group, an example 9 low-dose group, an example 9 medium-dose group, an example 9 high-dose group, an example 10 group, an example 11 group and a astragalus membranaceus qi-tonifying dropping pill group, wherein each group comprises 10 rats.

Blank group sham treatment: the same needle with the same size was used for the anterior descending branch of the left coronary artery between the lower edge of the left atrial appendage and the pulmonary artery cone of 10 normal rats without knotting, and the rest of the procedure was the same as above.

2.3 administration of drugs

The groups of example 7, example 9 low dose group, example 9 medium dose group, example 9 high dose group, example 10 group, example 11 group, and astragalus membranaceus-ginseng qi-tonifying drop pill group are administered with corresponding drugs according to 1.2.2; blank group, model group were given equal doses of saline and given for 30 days.

3. Project index detection

3.1 measurement of CK-MB, c-TNT and LDH content in rat aorta serum

After 30 days of administration, the rats are opened, abdominal aorta is exposed, 3-4ml of blood is taken, supernatant serum is taken by centrifugation, and the content levels of CK-MB, c-TNT and LDH in the rat aorta serum are detected.

3.2 immunohistochemical expression detection of angiogenic VEGF protein in myocardial infarction marginal zone of rat post-infarction

Immunohistochemistry was used to detect VEGF (C-1) expression in the myocardium of rats in the infarct zone.

4. Statistics of results

4.1 levels of CK-MB, c-TNT, LDH in rat aorta serum

As shown in FIGS. 1-3, the CK-MB, c-TNT and LDH content levels in rat aortic blood serum are rat myocardial damage markers, and the results show that compared with the model group, the differences of the group 7, the group 9 with low dose, the group 9 with medium dose, the group 9 with high dose, the group 10 with example and the group 11 with example are statistically significant, and P is less than 0.01.

4.2 immunohistochemical expression of neovascular VEGF protein in the myocardium in the infarct border zone of rats

TABLE 5 immunohistochemical expression of angiogenic VEGF protein in myocardial infarct border zone of groups of rats: (

n＝10)

Note: p < 0.01 as compared to blank;

in contrast to the model set,^#P＜0.01。

FIGS. 4-5 are descriptive statistics and multiple comparisons of significant differences for immunohistochemical expression of angiogenic VEGF protein in myocardium at infarct border zone of rats in each group. Groups 1-9 in the figure correspond to blank group, model group, example 7 group, example 9 low dose group, example 9 medium dose group, example 9 high dose group, example 10 group, example 11 group, and qi-replenishing astragalus-ginseng drop pill group, respectively. The results show that compared with the blank group (1), the model group, the example 7 group, the example 9 low dose group, the example 9 medium dose group, the example 9 high dose group, the example 10 group, the example 11 group and the astragalus-ginseng qi-tonifying pill group (2-9) have the difference of less than 0.01 and have statistical significance; compared with the model group (2), the group 7, the group 9 with low dose, the group 9 with medium dose, the group 9 with high dose, the group 10, the group 11 and the group (3-9) of astragalus and ginseng qi-tonifying dropping pills have the difference of less than 0.01 and have statistical significance; compared with the qi-tonifying dripping pill group (9), the groups of 7, 9 and 9, the middle-dose group of 9, the high-dose group of 9, 10 and 11 (3-8) have statistical significance for the difference that P is less than 0.01.

2. The traditional Chinese medicine composition has the treatment effect on angina pectoris type coronary heart disease rats

1 materials

1.1 animals:

SD rat, SPF grade, 180-220g, laboratory animal license number: SYXK (U) 2018 0008, provided by the pharmaceutical group of Lunan, inc., was acclimatized for one week prior to the experiment.

1.2 drugs

1.2.1 medicaments

Example 9 mixture of the invention

Example 10 mixture of the present invention

Example 11 mixture of the present invention

Comparative example 1 mixture

Comparative example 2 mixture

Comparative example 3 mixture

1.2.2 doses

Example 10 of the present invention mixture: 1.8ml/kg

Example 11 mixture of the present invention: 1.8ml/kg

Comparative example 1 mixture: 3.6ml/kg

Comparative example 2 mixture: 3.6ml/kg

Comparative example 3 mixture: 3.6ml/kg

2. Modeling, grouping and administering drugs

2.1 Atherosclerosis rat modeling method

90 normal rats were taken, subjected to sevoflurane inhalation anesthesia, fixed on an operating table in a supine position, dissected and separated from femoral veins, subjected to intravenous catheterization, and injected with posterior pituitary pituitrin at 30U/kg/d for three consecutive days.

2.2 grouping

A total of 87 rats were successfully molded, and 80 rats successfully molded were randomly divided into a model group, a low dose group in example 9, a medium dose group in example 9, a high dose group in example 9, a group in example 10, a group in example 11, a group in comparative example 1, a group in comparative example 2, and a group in comparative example 3, each group consisting of 10 rats.

In the blank group, 10 normal rats were selected, and the sham operated group was prepared and injected with the same amount of physiological saline.

2.3 administration of drugs

The example 9 low dose group, the example 9 middle dose group, the example 9 high dose group, the example 10 group, the example 11 group, the comparative example 1 group, the comparative example 2 group, and the comparative example 3 group were each administered with the corresponding drug according to 1.2.2; blank group, model group were given equal doses of saline and given for 30 days.

3. Project index detection

3.1 TXB2, 6-Keto-PGF in rat plasma_1αExpression of content

Collecting blood from aorta, adding EDTA-Na2 0.1mL, mixing, centrifuging at 4 deg.C 350r/min for 10min, separating plasma, and measuring TXA by radioimmunoassay₂、PGI₂The stable metabolites TXB2, 6-Keto-PGF_1α。

3.2 expression level of NO in rat serum

Collecting blood from aorta, centrifuging at 3000r/min for 15min, collecting supernatant, and detecting serum NO by nitric acid reductase method.

3.3 rat serum plasma ET-1 expression levels

Collecting blood from aorta, adding EDTA-Na 215 μ L and aprotinin 20 μ L7.5%, mixing, centrifuging at 4 deg.C 3000r/min for 10min, separating plasma, and measuring plasma ET-1 by radioimmunoassay.

4. Statistics of results

4.1 TXB in rat plasma₂、6-Keto-PGF_1αExpression of content

As shown in FIGS. 6-7, they are TXB in rat plasma₂(pmol/L)、6-Keto-PGF_1α(pmol/L) content expression, and the results show that compared with the model group, the differences of the low-dose group in the invention example 9, the medium-dose group in the invention example 9, the high-dose group in the invention example 9, the group in the invention example 10 and the group in the invention example 11 are all statistically significant, and P is less than 0.01.

4.2 expression level of NO in rat serum

TABLE 6 serum NO expression level in rats of each group: (

n＝10)

Note: p < 0.01 as compared to blank;

in contrast to the model set,^#P＜0.01，@P＜0.05。

FIGS. 8-9 show the descriptive statistics and multiple comparisons of significant differences for statistics of the NO expression level SPSS22.0 data in serum of rats in each group. In the figure, groups 1 to 10 correspond to the blank group, the model group, the example 9 low dose group, the example 9 medium dose group, the example 9 high dose group, the example 10 group, the example 11 group, the comparative example 1 group, the comparative example 2 group and the comparative example 3 group, respectively, and the results show that the model group, the example 9 low dose group, the example 9 medium dose group, the example 9 high dose group, the example 10 group, the example 11 group, the comparative example 1 group, the comparative example 2 group and the comparative example 3 group (2 to 10) have statistical significance in P < 0.01 when compared with the blank group (1); compared with the model group (2), the group of the low dose in the example 9, the group of the medium dose in the example 9, the group of the high dose in the example 9, the group of the example 10, the group of the example 11 and the group of the comparative example 3 (3-7 and 10) have the difference of less than 0.01 and have statistical significance; compared with the model group (2), the group of comparative example 1 and the group of comparative example 2 (8-9) have P < 0.05.

4.3 rat serum plasma ET-1 expression levels

As shown in FIG. 10, the ET-1 content in rat plasma is expressed, and the results show that the differences of the low dose group in example 9, the high dose group in example 10 and the group in example 11 are statistically significant, and P is less than 0.01, compared with the model group.

The pharmacodynamic data is statistically analyzed by SPSS22.0 software, and the data is measured

Is represented by P<0.05 is statistically significant, and only part of the statistical analysis process is shown here.

Claims

1. A Chinese medicinal composition is characterized by comprising, by weight, 5-80 parts of radix bupleuri, 20-100 parts of fructus aurantii, 6-90 parts of radix curcumae, 40-100 parts of rhizoma cyperi, 20-100 parts of ligusticum wallichii, 5-50 parts of lumbricus, 2-40 parts of leech, 20-100 parts of radix paeoniae rubra and 5-80 parts of peach kernel.

2. The traditional Chinese medicine composition of claim 2, wherein the traditional Chinese medicine composition further comprises, by weight, 10-100 parts of pericarpium citri reticulatae viride, 20-100 parts of pericarpium citri reticulatae, 80-200 parts of angelica sinensis, 100-300 parts of radix rehmanniae, 5-100 parts of safflower, 20-300 parts of radix achyranthis bidentatae, 2-20 parts of asarum and 120-200 parts of platycodon grandiflorum.

3. The traditional Chinese medicine composition according to claim 3, wherein the traditional Chinese medicine composition comprises the following components in parts by weight:

4. use of the Chinese medicinal composition of any one of claims 1 to 3 in the preparation of a medicament for the treatment of cardiovascular diseases.

5. Use according to claim 4, characterized in that the cardiovascular disease is coronary heart disease.

6. The use of claim 4, wherein the Chinese medicinal composition can relieve and/or improve symptoms of coronary heart disease such as hypodynamia, chest distress, chest pain, palpitation, short breath and the like.

7. The use of claim 4, wherein the composition is effective for lowering lipid and improving hemorheology.

8. The Chinese medicinal composition according to any one of claims 1 to 3, wherein the Chinese medicinal composition can be prepared into a preparation directly or after adding pharmaceutically acceptable auxiliary materials.

9. A pharmaceutical composition comprising the Chinese medicinal composition of any one of claims 1 to 3, wherein the pharmaceutical composition further comprises a chemical agent for treating coronary heart disease.